

CURRICULUM VITAE**Joseph Unger, Ph.D.****1. PERSONAL DATA**Contact Information

Public Health Sciences, Biostatistics Program
 SWOG Cancer Research Network Statistical
 Center 1100 Fairview Avenue, M3-C102
 Seattle, WA 98109-1024
 Phone: (206) 667-2860
 junger@fredhutch.org

2. EDUCATION

1986-1990	BS, Mathematics, Pomona College, Claremont, CA
1991-1993	MS, Biostatistics, University of Washington, Seattle, WA
2009-2013	PhD, Health Services Research, University of Washington, Seattle, WA

3. LICENSURE

N/A

4. PROFESSIONAL POSITIONS HELD

2013–2015	Staff Scientist: Fred Hutchinson Cancer Center, Public Health Sciences Division, Seattle, WA
2016–2021	Affiliate Assistant Professor: University of Washington, Department of Health Systems and Population Health, School of Public Health, Seattle, WA
2015–2020	Assistant Member: Fred Hutchinson Cancer Center, Public Health Sciences Division, Seattle, WA
2021–present	Affiliate Associate Professor: University of Washington, Department of Health Systems and Population Health, School of Public Health, Seattle, WA
2020–present	Associate Professor: Fred Hutchinson Cancer Center, Public Health Sciences Division, Seattle, WA
2025-present	Professor, Fred Hutchinson Cancer Center, Public Health Sciences Division, Seattle, WA

5. HONORS

2009	Included in ASCO's Clinical Cancer Advances 2009 [J Clin Oncol, 2009 Dec 10;27(35):6052-69]: <ul style="list-style-type: none"> Hershman DL, Unger JM, et al. Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology Group Studies S8814/S8897. J Clin Oncol. 2009 May 1;27(13):2157-62.
2010	Included in ASCO's Clinical Cancer Advances 2010 [J Clin Oncol, 2010 Dec 20;28(36):5327-47]: <ul style="list-style-type: none"> Albain KS, Unger JM, et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009 Jul 15;101(14):984-92.
2012	Included in ASCO's Clinical Cancer Advances 2012 [J Clin Oncol, 2013 Jan 1;31(1):131-61]: <ul style="list-style-type: none"> Unger JM, et al: Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura. J Clin Oncol 30:384s, 2012 (suppl; abstr CRA6009)
2013	Outstanding Student, Doctoral Health Services, University of Washington School of Public Health

- 2015 Included in ASCO's Clinical Cancer Advances 2015 [J Clin Oncol, 2015 Mar 1;33(7):786-809]:
- Moore HCF, Unger JM, et al. Goserelin for Ovarian Protection during Breast Cancer Adjuvant Chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32.
- 2015 Coltman Fellowship Award winner, the HOPE Foundation
- 2017 Included in ASCO's Clinical Cancer Advances 2017 [J Clin Oncol, 2017 Apr 20;35(12):1341-67]:
- Unger JM, et al. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol. 2016 Jan 1;2(1):137-9.
- 2019 Outstanding Article of the Year, Second Place, the International Society for Quality of Life Research (ISOQOL) Annual Meeting, October 23, 2019, San Diego, Ca.
- Unger JM, et al. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial. J Patient Rep Outcomes. 2018 Jun 13;2:27.
- 2019 Awarded the SWOG/Hope Foundation Impact Award by The Hope Foundation for Cancer Research
- 2020 American Cancer Society Research Scholar Grant Award Winner
- 2021 Included in ASCO's Clinical Cancer Advances 2021 [J Clin Oncol, 2021 Apr 1;39(10):1165-1184]:
- Unger JM, et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. J Natl Cancer Inst. 2019 Mar 1;111(3):245-255.
 - Unger JM, et al. The role of clinical trial participation in cancer research: Barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185-198
 - Loree JM, Anand S, Dasari A, Unger JM, et al. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol. 2019 Aug 15:e191870.
- 2022 Awarded the "Alan Lyss Award for Leadership in Community Cancer Research" by the Heartland Cancer Research National Community Oncology Research Program

6. PROFESSIONAL ACTIVITIES

- 2015 SWOG Cancer Research Network, Search Committee Member, SWOG Symptom Control and Quality of Life Committee Co-Chair
- 2016–current SWOG Cancer Research Network, Publications Committee Member
- 2016–current SWOG Cancer Research Network, NCORP Executive Committee Member
- 2016–2018 National Cancer Institute, Landscape Survey Working Group
- 2016–current National Cancer Institute, Symptom Management and Quality of Life Steering Committee
- 2017–2023 National Cancer Institute, ePRO (electronic Patient Reported Outcomes) Working Group
- 2017 SWOG Cancer Research Network, Search Committee Member, SWOG Survivorship Committee Co-Chair
- 2017 National Cancer Institute, Chemotherapy-Induced Peripheral Neuropathy (CIPN) Longitudinal Study Working Group
- 2017–2020 American Cancer Society Cancer Action Network, Clinical Trial Enrollment Project Steering Committee
- 2018–2024 National Cancer Institute, Cancer Care Delivery Research Steering Committee
- 2019 – 2021 FDA-AACR, Workshop to Examine Under-representation of African Americans

	in Multiple Myeloma Clinical Trials – Session Chair
2020–current	National Cancer Institute, Division of Cancer Prevention and Division of Cancer Treatment and Diagnosis planning team member: “Engaging Older Adults in the NCI Clinical Trials Network: Challenges and Opportunities”
2021	National Cancer Institute, Cancer-Related Cognitive Impairment Clinical Trials Working Group
2021–current	National Cancer Institute Cancer Moonshot, Consortium on Tolerability of Cancer Treatment
2021–current	Chair, American Society of Clinical Oncology/Friends of Cancer Research, Task Force Research Project on the Impact of the COVID-19 Pandemic on Clinical Trial Protocol Adherence and Fidelity
2022–current	AACR Cancer Disparities Research Grants Scientific Review Committee
2024–current	FDA-American Cancer Society Working Group on Clinical Trial Diversity
2024–current	ASCO Quality Care Program Committee
2024–current	American Society of Clinical Oncology Research Committee for the Center for Research and Analytics (CENTRA)

7. BIBLIOGRAPHY

A. Publications in Refereed Journals

† Denotes senior author

* Denotes co-first author

1. Henry NL, **Unger JM**, Vaidya R, Darke A, Skaar T, Fisch MJ, Hershman DL. Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial. *Contemp Clin Trials*. 2024. In press. [original article]
2. † Vaidya R, Till C, Henry NL, Fisch MJ, Hershman DL, **Unger JM**. Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer. *Breast Cancer Res Treat*. 2024. In press. [original article]
3. † Presant CA, Till C, Vaidya R, Ashing KT, Warrant GW, Sun V, Salgia R, Massarelli E, Mortimer JE, Pal S, Dorff T, Amini A, Erhunmwunsee L, Phillips T, Hershman DL, **Unger JM**. Smoking Prevalence and Association with Sociodemographic Variables in Cancer Clinical Trial Participants. *Cancer*. 2024 Sep 16. [original article]
4. **Unger JM**, Till C, Tangen CM, Hershman DL, Goodman PJ, LeBlanc M, Barlow WE, Vaidya R, Minasian LM, Parnes HL, Thompson Jr. IM. Long-term side effects and complications after prostate cancer treatment. *JAMA Oncol*. In press. [original article]
5. Dressler EV, Pugh SL, **Unger JM**, Gunn HL, Zahrieh D, Snaveley AC. Cluster randomized trials in NCORP Cancer Care Delivery Studies. *JNCI Monograph*. In press. [original article]
6. **Unger JM**, Xiao H, Vaidy R, LeBlanc M. Patient Enrollment to Industry versus NIH Sponsored Cancer Clinical Trials. *J Clin Oncol*. 2024 Sep 27:JCO2400843. [original article]
 - **Editorial:** Abdou Y, Sharpless NE. Bridging the Gap in Cancer Clinical Trial Funding. *J Clin Oncol*. 2024 Sep 27:JCO2401484. doi: 10.1200/JCO-24-01484.
7. **Unger JM**, Mazza GL, Elsaid MI, Duan F, Dressler EV, Snaveley AC, Enserro DM, Pugh SL. When to Adjust for Multiplicity in Cancer Clinical Trials. *JNCI Monograph*. In press. [original article]
8. † Mazza GL, Culakova E, Enserro DM, Dignam JJ, **Unger JM**. Design and Analysis Considerations for Investigating Patient Subgroups of Interest within Cancer Clinical Trials. *JNCI Monograph*. In press. [original article]
9. Bandos H, Torres-Saavedra PA, Culakova E, Gunn H, Lee MK, Duan F, Cecchini RS, **Unger JM**, Dueck AC, Steingrimsson JA. Best Practices and Pragmatic Approaches for PRO/QOL Measures in Cancer Clinical Trials. *JNCI Monograph*. In press. [original article]

10. † Xiao H, Vaidya R, Hershman DL, **Unger JM**. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. *J Clin Oncol*. 2024 Mar 27;JCO2301777. [original article]
11. † Hershman DL, Vaidya R, Till C, Barlow WE, LeBlanc M, Ramsey SD, **Unger JM**. Socioeconomic Deprivation and Health Care Use in Patients Enrolled in SWOG Cancer Clinical Trials. *JAMA Netw Open*. 2024 Mar 4;7(3):e244008. [original article]
12. **Unger JM**, Schulman LN, Facktor MA, Nelson H, Fleury ME. National Estimates of the Participation of Patients with Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data. *J Clin Oncol*. 2024 Jun 20;42(18):2139-2148. [original article]
 - **Media:** MSN, UPI, US News and World Report; <https://www.altmetric.com/details/161472555/news>
 - **Television:** KOMO News Live, April 3, 2024.
13. Vaidya RR, **Unger JM**, Loomba R, Hwang JP, Chugh R, Tincopa MA, Arnold K, Hershman DL, Ramsey SD. Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation. *Cancer Res Commun*. 2023 Sep 28;3(9):1959-1965. [original article]
14. Bell-Brown A, Watabayashi K, Delaney D, Hershman DL, Ramsey SD, Carlos RC, Langer SL, **Unger JM**, Vaidya RR, Darke AK, Shankaran V. Assessment of Financial Screening and Navigation Capabilities at NCI Community Oncology Clinics. *JCNI CS*. 2023 Aug 31;7(5):pkad055. [original article]
15. † Xiao H, Wang Z, Liu F, **Unger JM**. Excess All-Cause Mortality in China After Ending the Zero COVID Policy. *JAMA Netw Open*. 2023 Aug 1;6(8):e2330877. [original article]
 - **Media:** Reuters, NBC News, Bloomberg Business, CNBC, MSN, CNN, Yahoo! News, Der Spiegel, The Telegraph (UK): <https://jamanetwork.altmetric.com/details/153279307#score>
16. Vaidya R, **Unger JM**, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar S, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray J, Redman MW. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). *JCO Precis Medic*. 2023 Sep;7:e2300218. [original article]
17. **Unger JM**. A Ground's Eye View on Racial and Ethnic Disparities in Cancer Clinical Trial Participation. *JAMA Netw Open*. 2023 Jul 3;6(7):e2322436. [invited commentary]
18. **Unger JM**, Xiao H, Vaidya R, LeBlanc M, Hershman DL. Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients with Medicaid in Cancer Clinical Trials. *JAMA Oncol*. 2023 Aug 17:e232800. [original article]
 - **Commentary:** Obeng-Gyasi S, Fayanju OM, "Medicaid Expansion and Clinical Trials", *JAMA Oncol*, 2023.
19. **Unger JM**, Stires H, Levit LA, Stewart M, McKelvey BA, Canin B, Connelly N, Dressler E, Flaherty K, Fredette P, Jones L, McCann P, Miller T, Ontilo AA, Palmieri F, Patel T, Paul R, Smith GL, Bruinooge SS, Garrett-Mayer E, Lei XJ, Alva A, Schenkel C. Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality. *JCO Oncol Pract*. 2023 Oct;19(10):907-916. [original article]
20. Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, Hershman DL, **Unger JM**, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. *JAMA Netw Open*. 2023;6(5):e2311673.

21. † Xiao H, Guo Y, Wang Z, Liu F, **Unger JM**. Dynamic zero-COVID policy and healthcare utilization patterns in China during the Shanghai COVID-19 Omicron outbreak. *Commun Med (Lond)*. 2023 Oct 11;3(1):143. [original article]
22. † Lee SM, Fan W, Wang A, Vaidya R, Redman MW, Gettinger SN, Bazhenova L, Herbst RS, Hershman DL, **Unger JM**. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). *JCO Clin Cancer Inform*. 2023 Apr;7:e2200165. [original article]
23. **Unger JM**, Till C, Hwang JP, Arnold KB, LeBlanc M, Hershman DL, Ramsey SD. Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients. *J Natl Cancer Inst*. 2023 Mar 22:djad053. [original article]
24. † Xiao H, Liu F, **Unger JM**. Automatic electronic reporting improved the completeness of AMI and stroke incident surveillance in Tianjin, China: A Modeling Study. *Popul Health Metr*. 2023 Feb 6;21(1):2. [original article]
 - **Media:** Axios, Seattle Times, ~40 other outlets: <https://jamanetwork.altmetric.com/details/139699871>
 - **Radio:** KIRO news radio.
25. **Unger JM**, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Papdimitrakopoulou VA, LeBlanc M, Cleeland CS, Dzingale SA, Summers TJ, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray JE, Kelly KL, Gandara DR, Bazhenova L, Herbst RS, Gettinger SN, Moinpour CM. Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I. *J Natl Cancer Inst*. 2023 Apr 11;115(4):437-446. [original article]
 - **Commentary:** Jim et al., “The importance of patient-reported outcomes in pragmatic clinical trials”, JNCI, 2023.
26. Shankaran V, Carlos RC, Hershman DL, Langer S, Ramsey SD, **Unger JM**, Darke AK, Vaidya R. A Randomized Trial Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention (CREDIT): SWOG S1912. *Trials*. In press. [original article]
27. Le-Rademacher J, Mohile S, **Unger J**, Hudson MF, Foster J, Lichtman S, Perlmutter J, Dotan E, Extermann M, Dodd K, Tew W, Klepin H, Wildes TM, Sedrak MS, Jatoi A, Little RF. Trial Design Considerations to Increase Older Accrual to National Cancer Institute Clinical Trials. *JNCI Monographs*, Volume 2022, Issue 60, December 2022, Pages 135–141. [original article]
28. **Unger JM**. Lost in Translation: The Participation in Cancer Clinical Trials for Patients with Limited English Proficiency. *J Natl Compr Canc Netw*. 2023 Jan;21(1):99-100. [commentary]
29. Hwang JP, Arnold KB, **Unger JM**, Chugh R, Tincopa MA, Loomba R, Hershman DL, Ramsey SD. Antiviral Therapy Use and Related Outcomes in Patients with Cancer and Viral Infections: Results from SWOG S1204. *Support Care Cancer*. 2022 Dec 31;31(1):93.
30. **Unger JM**, LeBlanc M, George S, Wolmark N, Curran WJ, O'Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. *J Clin Oncol*. 2023 Apr 10;41(11):2020-2028. [original article]
 - **Media:** Healio, Medscape, MedicalEpress, Mirage News, EurekAlert!
 - **Invited Commentary:** Howard A. Burris III, MD, “The National Clinical Trials Network: A Valuable and Undervalued Resource”
 - **NCI Director (Dr. Bertagnolli):** “This result validates the key role of NCTN and other networks in improving the outlook for patients with cancer and progressing toward our goal to reduce the cancer death rate by half within 25 years.”

31. † Xiao H, Vaidya R, Liu F, Chang X, Xia X, **Unger JM**. Sex, Racial, and Ethnic Representation in COVID-19 Clinical Trials: A Systematic Review and Meta-Analysis. *JAMA Intern Med*. 2023 Jan 1;183(1):50-60. [original article]
32. Hershman DL, **Unger JM**, Greenlee H, Capodice J, Lew DL, Darke A, Minasian LM, Fisch MJ, Henry NL, Crew KD. Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial. *JAMA Netw Open*. 2022 Nov 1;5(11):e2241720. [original article]
 - Media: ~40 outlets: <https://jamanetwork.altmetric.com/details/138293976/news>
33. **Unger JM**, Darke A, Othus M, et al. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. *JAMA Oncol*. 2023 Feb 1;9(2):251-260. [original article]
34. † Jones SMW, Gaffney A, **Unger JM**. Common Methods of Determining Meaningful Change in Clinical Practice: Implications for Precision Patient-Reported Outcomes. *Qual Life Res*. 2022 Sep 10. doi: 10.1007/s11136-022-03246-4. Online ahead of print. [original article]
35. Rock M, Vaidya R, Till C, **Unger JM**, Hershman DL, Ramsey SD, Nehemiah A, Maeng D, and Krouse RS. Racial and Ethnic Disparity in Preference-Weighted Quality of Life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Popul Health Manag*. 2023 Jan 10. Online ahead of print. [original article]
36. Ellis SD, Vaidya R, **Unger JM**, Stratton K, Gills J, Van Veldhuizen P, Mederos E, Dressler EV, Hudson MF, Kamen C, Neuman HB, Kazak AE, Carlos RC, Weaver KE. Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey. *Contemp Clin Trials Commun*. 2022 Aug 14;29:100981. [original article]
37. † Vaidya R, Till CT, Greenlee H, Hershman DL, **Unger JM**. Trends in Obesity Prevalence Among Patients Registered to Cancer Clinical Treatment Trials. *JAMA Netw Open*. 2022 Oct 3;5(10):e2234445. [original article]
38. † Nghiem VT, Vaidya R, **Unger JM**. Patterns of Scientific and Clinical Impact in Cancer Randomized Clinical Trials. *JAMA Netw Open*. 2022 Jun 1;5(6):e2219657. [original article]
39. † Wang Z, Xiao H, Lin L, Tang K, **Unger JM**. Geographic social inequalities in information-seeking response to the COVID-19 pandemic in China: longitudinal analysis of Baidu Index. *Sci Rep*. 2022 Jul 18;12(1):12243. [original article]
40. Tilley BC, Mainous AG 3rd, Amorrortu RP, McKee MD, Smith DW, Li R, DeSantis SM, Vernon SW, Koch G, Ford ME, Diaz V, Alvidrez J, additional RECRUIT Trial Center and Parent Trials' investigators* (*includes **Unger JM**). Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial. *Contemp Clin Trials*. 2021 Oct;109:106519. doi: 10.1016/j.cct.2021.106519. Epub 2021 Jul 30. PubMed PMID: 34333138. [original article]
41. Rutherford SC, Yin J, Pederson L, Burbano GP, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Uijani C, Barr PM, **Unger JM**, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar S, Leonard JP. Relevance of bone marrow biopsies for response assessment in U.S. National Cancer Institute National Clinical Trials Network follicular lymphoma clinical trials. *J Clin Oncol*. 2023 Jan 10;41(2):336-342. [original article]

42. † Jones SMW, **Unger JM**. Feasibility of a Patient-Centered Method to Determine Meaningful Change in Pain Intensity on a Survey of Patients with a History of Cancer. *Pain Rep*. 2022 Jun 6;7(4):e1015. [original article]
43. **Unger JM**. Cancer Care During COVID-19 – A Shock to the System. *JAMA Netw Open*. 2022 April 1;5(4):e228864. [invited commentary]
44. **Unger JM**, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, Henry NL, Fisch MJ, Lee SM, Blanke CD, Hershman DL. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. *J Clin Oncol*. 2022 May 1;40(13):1474-1486. [original article]
▪ **Media:** Reuters, Forbes, UPI, MSN, US News and World Report, Stat News, HemOnc Today, UK Today News, Sky Italia, El Pais, El Espectador, La Nacion, Nouvelles du Monde. 82 news outlets:
<https://www.altmetric.com/details/122202639?src=bookmarklet>
45. † Jones SMW, **Unger JM**. Tailoring Pain Interference Measurement in People with Cancer: A Feasibility Study. *Journal of Pain and Symptom Management*. 2022 Feb 27:S0885-3924(22)00416-X. [original article]
46. Chen Y, Ji X, Xiao H, **Unger JM**, Cai Y, Mao Z, Yeung K. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls. *Front Pharmacol*. 2021 Dec 22;12:804237. [original article]
47. † Xiao H, He Y, Dai X, Liu F, Liu Z, **Unger JM**. Unequal impact of the COVID-19 pandemic on pediatric cancer care: a population-based cohort study in China. *Lancet Regional Health-Western Pacific*. 2022 Feb;19:100347. [original article]
48. Henry LN, **Unger JM**, Till C, Crew KD, Fisch MJ, Hershman DL. Predictors of pain reduction in trials of interventions for aromatase inhibitor-associated musculoskeletal symptoms. *JNCI Cancer Spectr*. 2021 Oct 30;5(6):pkab087. [original article]
49. Shankaran V, **Unger JM**, Darke AK, Suga JM, Wade III JL, Kourlas PJ, Chandana SR, O'Rourke MA, Satti S, Liggett D, Hershman DL, Ramsey SD. S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. *J Natl Cancer Inst*. 2022 Mar 8;114(3):372-380. [original article]
▪ **Media:** 47 news outlets: <https://oxfordjournals.altmetric.com/details/120203150>
50. † Jones SMW, Gaffney A, **Unger JM**. A Comparison of Oncologist versus Mental Health Provider Attitudes Towards Standardized and Tailored Patient-Reported Outcomes. *J Patient Rep Outcomes*. 2021 Aug 24;5(1):76. [original article]
51. Hui D, Darke AK, Guthrie KA, Subbiah IM, **Unger JM**, Hershman DL, Krouse RS, Bakitas M, O'Rourke MA. Association between Health-Related Quality of Life and Progression Free Survival in Patients with Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. *JCO Oncol Pract*. 2021 Oct 4:OP2100407. Online ahead of print. [original article]
52. Oster NV, Williams EC, **Unger JM**, Newcomb PA, deHart MP, Englund JA, Hofstetter AM. A Risk Prediction Model to Identify Newborns at Risk for Missing Early Childhood Vaccinations. *J Pediatric Infect Dis Soc*. 2021 Aug 17:piab073. [original article]
53. **Unger JM**, Beauchemin M, Hershman DL. Accrual of Adolescent and Young Adult Patients to A National Cancer Institute-Sponsored National Clinical Trials Network Research Group Over 25 Years. *Cancer*. 2021 Aug 5. doi: 10.1002/cncr.33855. Online ahead of print [original article]

54. **Unger JM**, Xiao H, LeBlanc M, Hershman DL, Blanke CD. Cancer Clinical Trial Participation At the One Year Anniversary of the Outbreak of the COVID-19 Pandemic. *JAMA Netw Open*. 2021 Jul 1;4(7):e2118433. [original article]
55. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, **Unger JM**, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. *JAMA Onc*. 2021 Sep 1;7(9):1368-1377. [original article]
56. Gormley N, Fashoyin-Aje L, Locke T, **Unger JM**, Little RF, Nooka A, Mezzi K, Popa-McKiver M, Kobos R, Biru Y, Williams TH, Anderson KC. Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step towards Achieving Equity in Healthcare. *Cancer Discov*. 2021 Mar;2(2):119-124. [review]
57. Mo J, Darke AK, Guthrie KA, Sloan JA, **Unger JM**, Hershman DL, Krouse RS. The Association of Patient Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. *JCO Oncol Pract*. 2021 Jul 13:OP2001096. [original article]
58. Sanchez JI, Shankaran V, **Unger JM**, Madeleine MM, Espinoza N, Thompson B. Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors. *J Cancer Surviv*. 2022 Jun;16(3):638-649. doi: 10.1007/s11764-021-01057-z.
59. **Unger JM**. Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials. *JAMA Netw Open*. 2021 Apr 20;4(4):e217159 [invited commentary]
60. **Unger JM**, Xiao H. The COVID-19 pandemic and new clinical trial activations. *Trials*. 2021 Apr 8;22(1):260. [original article]
61. † Xiao H, Dai X, Wagenaar BH, Liu F, Augusto O, Guo Y, **Unger JM**. The impact of the COVID-19 pandemic on health services utilization in China: Time-series analyses for 2016–2020. *Lancet Reg Health West Pac*. 2021 Mar 24;9:100122. [original article]
62. Osarogiagbon RU, Sineshaw HM, **Unger JM**, Acuña-Villaorduña A, Goel S. Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. *Am Soc Clin Oncol Educ Book*. 2021 Mar;41:1-13. [original article]
63. † Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, **Unger JM**. Patient Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. *J Natl Cancer Inst*. 2021 Aug 2;113(8):989-996. [original article]
64. **Unger JM**, Moseley AB, Cheung CK, Osarogiagbon RU, Symington B, Ramsey SD, Hershman DL. Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. *J Clin Oncol*. 2021 Mar 17:JCO2002602. [original article]
 - **Media:** HemOnc Today, Healio, Health Day, ScienMag, Renal and Urology News, eCancer, Clinical Advisor, Doctors Lounge, Drugs.Com, MedicalXpress
65. Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney D, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, **Unger JM**, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG 1400GEN). *JCO Oncol Pract*. 2021 Apr 2:OP2000770. [original article]

66. † Hershman DL, Moseley A, Hillyer GC, Arnold KB, Gralow JR, Henry NL, Ramsey SD, Neugut AI, **Unger JM**. Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. *J Natl Cancer Inst*. 2021 Aug 2;113(8):989-996. [original article]
67. McLouth LE, Nightingale CL, Dressler EV, Snavely AC, Hudson MF, **Unger JM**, Kazak AE, Lee SJC, Edward J, Carlos R, Kamen CS, Neuman HB, Weaver KE. Current Practices for Screening and Addressing Financial Hardship within the National Cancer Institute's Community Oncology Research Program. *Cancer Epidemiol Biomarkers Prev*. 2021 Apr;30(4):669-675. [original article]
68. Sedrak MS, Sun CL, Hershman DL, **Unger JM**, Liu J, Dale W, Dizon DS. Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. *JAMA Netw Open*. 2020 Dec 1;3(12):e2031202. [research letter]
69. Hohl SD, Knerr S, Neuhouser M, Beresford SAA, **Unger JM**, Fishman P, Thompson B. Transdisciplinary research outcomes based on the Transdisciplinary Research on Energetics and Cancer (TREC) Initiative experience. *Research Evaluation*. 2020 Dec 25;rvaa026. [original article]
70. Goulart BHL, **Unger JM**, Chennupati S, Egan KS, Ramsey SD. Association of Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR and ALK Positive Advanced Non-Small Cell Lung Cancer. *JCO Oncol Pract*. 2021 Feb;17(2):e130-e139. [original article]
71. Nightingale CL, Sterba KR, McLouth LE, Kent EE, Dressler E, Dest A, Snavely A, Adonizio C, Wojtowicz M, Neuman HB, Kazak AE, Carlos R, Hudson MF, **Unger JM**, Kamen CS, Weaver KE. Caregiver Engagement Practices in the National Cancer Institute Clinical Oncology Research Program (NCORP) Settings: Implications for Research to Advance the Field. *Cancer*. 2021 Feb 15;127(4):639-647 [original article]
72. † Fleury ME, Farner AM, **Unger JM**. Association of the Coronavirus Disease-2019 (COVID-19) Outbreak with Patient Willingness to Enroll in Cancer Clinical Trials. *JAMA Oncol*. 2020 Nov 12;3205748. [research letter]
 - **Media:** NY Times, Forbes, Yahoo! Finance USA, Stat News, ScienMag, Nature News, OncLive, PR Newswire, Morning Star, MedPage Today, Cancer Therapy Advisor, The Medical News, Doc Wire News, Medscape, Medwire News, Cancer Network
73. Sanchez JI, Shankaran V, **Unger JM**, Madeleine M, Selukar S, Thompson B. Inequitable access to surveillance colonoscopy among Medicare beneficiaries with surgically resected colorectal cancer. *Cancer*. 2021 Feb 1;127(3):412-421. [original article]
74. Van Poznak CH, **Unger JM**, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhi SR, Lew DL, Wade III JL, Fisch MJ, Henry NL, Hershman DL, Gralow J. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. *JAMA Oncology*. 2021 Feb 1;7(2):246-254. [original article]
75. Mendis S, Anand S, Karasinska JM, Dasari A, **Unger JM**, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. *Oncologist*. 2021 Feb;26(2):107-114. [original article]
76. **Unger JM**, Hershman DL, Till C, Minasian LM, Osaogiagbon RU, Fleury ME, Vaidya R. "When offered to participate:" A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. *J Natl Cancer Inst*. 2020 Oct 6:djaa155. [original article]

- **Media:** Reuters Health, Medscape, Renal & Urology News, Doctor's Lounge, MedicalXpress, Physician's Briefing, Drugs.Com, Cancer Today
 - **Invited Commentary:** Brundage MD. Revisiting Barriers to Clinical Trials. *J Natl Cancer Inst.* 2020 Oct 6:djaa156
77. † Nghiem VT, Vaidya R, Lyman GH, Hershman DL, Ramsey SD, **Unger JM**. Economic evaluations in NCI-sponsored network cancer clinical trials. *Value in Health*. 2020 Dec;23(12):1653-1661. [original article]
 78. Shankaran V, **Unger JM**, Darke AK, Hershman DL, Ramsey SD. Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. *Contemp Clin Trials*. 2020 Aug;95:106037. [original article]
 79. Williams GR, Weaver KE, Lesser GJ, Dressler E, Winkfield KM, Neuman HB, Kazak AE, Carlos R, Gansauer LJ, Kamen CS, **Unger JM**, Mohile S, Klepin HD. Capacity to Provide Geriatric Specialty Care for Older Adults in Community Oncology Practices. *Oncologist*. 2020 Dec;25(12):1032-1038 [original article]
 80. Wong SF, **Unger JM**, Wade III JL, Wagner LI, Lacouture M, Humphries KC, Moseley A, Arnold K, Velasco Jr. MR, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Moinpour CM. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. *J Patient Reported Outcomes*. 2020 Jul 8;4(1):54. [original article]
 81. **Unger JM**, Blanke CD, LeBlanc M, Hershman DL. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. *JAMA Netw Open*. 2020;3(6):32010651. [research letter]
 - **Media:** MedPage Today, Medcity News, medwireNews
 - **Podcast:** JAMA Network Open Live interview and podcast: "COVID-19 Outbreak and Enrollment in Cancer Clinical Trials". June 9, 2020. Available at: https://www.youtube.com/watch?v=zgg62I_22OM
 82. **Unger JM**, Hershman DL, Osarogiagbon RU, Gothwal A, Anand S, Dasari A, Overman M, Loree JM, Raghav K. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. *JNCI Cancer Spectr*. 2020 Apr 24;4(4):pkaa034. [original article]
 - **Media:** Axios, Cancer Today, Doc Wire News, WebMD News
 83. † Hershman DL, Till C, Wright JD, Accordini M, Vaidya R, Barlow WE, Ramsey S, **Unger JM**. Healthcare Utilization and Cost of Care in Elderly Breast Cancer Patients Enrolled in SWOG Clinical Trials. *Breast Cancer Res Treat*. 2020 Jun;181(2):455-463. doi: 10.1007/s10549-020-05634-1. [original article]
 84. † Jones SMW, Du Y, Bell-Brown A, Bolt K, **Unger JM**. Feasibility and Validity of Asking Patients to Define Individual Levels of Meaningful Change on Patient-Reported Outcomes. *J Patient Cent Res Rev*. 2020 Jul 27;7(3):239-248. [original article]
 85. Cannioto RA, Hutson A, Dighe S, McCann W, McCann SE, Zirpoli GR, Barlow W, Kelly KM, DeNysschen CA, Hershman DL, **Unger JM**, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. *J Natl Cancer Inst*. 2020 Apr 2. pii: djaa046. [original article]
 86. **Unger JM**, Blanke SD, LeBlanc M, Barlow WE, Vaidya R, Ramsey SD, Hershman DL. Association of Patient Demographic Characteristics and Insurance Status With Survival in

- Cancer Randomized Clinical Trials With Positive Findings. *JAMA Network Open*. 2018 Apr 30;3(4):e203842. [original article]
- **Media:** United Press International, The Medical News, MedicalXpress, EurekAlert!
 - **Invited Commentary:** Snyder RA, Change GL. “Insurance Status as a Surrogate for Social Determinants of Health in Cancer Clinical Trials.”
87. Hershman DL, **Unger JM**, Hillyer GC, Moseley A, Arnold KB, Dakhil SR, Esparaz BT, Kuan MC, Graham ML, Lackowski DM, Edenfield WJ, Dayao ZR, Gralow JR, Ramsey SD, Neugut AI. Randomized trial of text-messaging to reduce early discontinuation of adjuvant aromatase inhibitor therapy in women with early stage breast cancer: SWOG S1105. *J Clin Oncol*. 2020 May 5;JCO1902699. [original article]
- **Media:** Clinical Advisor, e cancer, MedicalXpress, MedPage Today, The Medical News, EurekAlert!
88. † Minasian LM, **Unger JM**. What Keeps Patients Out of Clinical Trials? *JCO Oncol Pract*. 2020 Mar;16(3):125-127 [editorial]
89. Roth ME, **Unger JM**, O'Mara AM, Lewis MA, Budd T, Johnson RH, Pollock BH, Blanke C, Freyer DR. Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. *Cancer Med*. 2020 Mar;9(6):2146-2152. [original article]
90. Tran G, Harker M, Chiswell K, **Unger JM**, Fleury ME, Hirsch B, Miller K, d'Almada P, Tibbs S, Zafar SY. Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence. *JCO Clin Cancer Inform*. 2020 Jan;4:35-49. [original article]
91. Hershman DL, Accordini MK, Shen S, Buono D, Crew KD, Kalinsky K, Trivedi MS, Hur C, Hu J, **Unger JM**, Wright JD. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. *Cancer*. 2020 Apr 1;126(7):1541-1549. [original article]
92. Lipira L, Rao D, Nevin PE, Kemp CG, Cohn SE, Turan JM, Simoni JM, Andrasik MP, French AL, **Unger JM**, Heagerty P, Williams EC. Patterns of alcohol use and associated characteristics and HIV-related outcomes among a sample of African-American women living with HIV. *Drug Alcohol Depend*. 2020 Jan 1;206:107753. [original article]
93. Ambrosone CB, Zirpoli GR, Hutson A, McCann W, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, Hershman DL, **Unger JM**, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS. Dietary supplement use during chemotherapy and survival outcomes of breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221). *J Clin Oncol*. 2020 Mar 10;38(8):804-814. [original article]
- **Media:** Forbes, Reuters Health, Yahoo! News, Voice of America, Daily Mail, Cure, AsiaOne, MedPage Today, Healthline, Healio, Medical Daily, Voice of Asia, Drugs.com, Physician's Briefing, Medscape, EurekAlert!
94. Minasian L, Dimond E, Shelburne N, Desvigne-Nickens P, Davis M, Adhikari B, Fagerstrom F, Fabian C, Floyd J, **Unger JM**, Douglas PS, Mustian KM, Chow EJ, Lipshultz S, Hundley WG, Armenian S, Ky B. The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. *CardioOncology*. 2019 September;1(1):105-13. [original article]
- **Accompanying Viewpoint:** Bhatt DL. Birth and Maturation of Cardio-Oncology. 2019 September;1(1): 114-16
95. **Unger JM**. Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then Trust. *JAMA Oncol*. 2019 Sep 5. [invited editorial]

96. **Unger JM**, Nghiem VT, Hershman DL, Vaidya R, LeBlanc M, Blanke CD. Association of National Cancer Institute–Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. *JAMA Netw Open*. 2019 Sep;2(9):e1910593. [original article]
- **Media:** Healio, TrialSite News, Genomeweb, e cancer, The Medical News, MedicalXpress. Note: This paper was the subject of a joint press release with the NCI emphasizing the importance of its findings with respect to the NCI's Clinical Trials Network.
 - **Social Media:** Dr. Francis Collins, NIH Director; Dr. Doug Lowy, NCI Director
97. Lee SM, Miao J, Wu R, **Unger JM**, Cheung K, Hershman DL. A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. *Health Qual Life Outcomes*. 2019 Aug 22;17(1):146. [original article]
98. Loree JM, Anand S, Dasari A, **Unger JM**, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. *JAMA Oncol*. 2019 Aug 15:e191870. [original article]
- **Media:** Fortune, UPI.com, Stat News, Reuters Health, The ASCO Post, Healio, San Antonio Express-News, PharmaVoice, Medical News Today, Genomeweb, Everyday Health, TrialSite News, Medscape, AJMC, Mobi Health News, Pittsburgh Tribute Review, Newswise, MedicalXpress
99. † Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, **Unger JM**. Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. *Arch Osteoporos*. 2019 Jul 28;14(1):83. [original article]
100. **Unger JM**, Fleury ME. Reimbursing Patients for Participation in Cancer Clinical Trials. *JAMA Oncol*. 2019 Jul 1;5(7):932-34. [viewpoint]
- **Media:** HemOnc Today, Healio
101. Oster NV, Williams EC, **Unger JM**, Newcomb PA, Jacobson EN, DeHart PM, Englund JA, Hofstetter AM. Hepatitis B Birth Dose: First Shot at Timely Early Childhood Vaccination. *Amer J Prev Med*. 2019 Oct;57(4):3117-3124. [original article]
102. Lipira L, Williams EC, Nevin PE, Kemp CG, Cohn SE, Turan JM, Simoni JM, Andrasik MP, French AL, **Unger JM**, Heagerty P, Rao D. Religiosity, Social Support, and Ethnic Identity: Exploring "Resilience Resources" for African-American Women Experiencing HIV-Related Stigma. *J Acquir Immune Defic Syndr*. 2019 Jun 1;81(2):175–183. [original article]
103. Su Y, Huang J, Wang S, **Unger JM**, Arias-Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J. The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. *J Natl Cancer Inst*. 2020 Jan 1;112(1):55-62. [original article]
104. Carlos RC, Sicks JD, Chiles C, Gansauer L, Kamen CS, Kazak AE, Neuman HB, **Unger JM**, Weaver KE. Lung Cancer Screening in the National Cancer Institute Community Oncology Research Program: Availability and Service Organization. *J Am Coll Radiol*. 2019 Apr;16(4 Pt A):427-34. [original article]
105. Oster NV, Williams EC, **Unger JM**, Newcomb PA, Jacobson EN, deHart MP, Englund JA, Hofstetter AM. Sociodemographic, clinical and birth hospitalization characteristics and infant Hepatitis B vaccination in Washington State. *Vaccine*. 2019 Sep 10;37(38):5738-44. [original article]

106. Henry NL, **Unger JM**, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL 3rd, Hershman DL. Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. *Cancer*. 2019 Jun 15;125(12):2123-29. [original article]
107. **Unger JM**, Vaidya R, Hershman DL, Minasian LM, Fleury M. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician/Patient Barriers to Cancer Clinical Trial Participation. *J Natl Cancer Inst*. 2019 Mar 1;111(3):245-55. [original article]
 - **Media:** BBC Radio, Reuters Health, Forbes, Health Affairs, Daily Mail, World Economic Forum, Cancer Today, Cure, Healio, Healthline, Medical Health News, Medscape, HealthDay, TrialSite News, Wired.com, ecancer, MedicalXpress, Doctors Lounge
 - **Social Media:** Dr. Francis Collins
108. **Unger JM**, Hershman D, Fleury ME, Vaidya R. Association of Patient Comorbid Conditions with Cancer Clinical Trial Participation. *JAMA Oncol*. 2019 Mar 1;5(3):326-33. [original article]
 - **Media:** Cancer Today, Cure, HealthDay, Hutch News, Medscape, EurekAlert!, MedicalXpress, MedPage Today, eCancer, Drugs.com, Physician's Briefing, AJMC, Oncology Nurse Advisor, Renal & Urology News, Medical Health News, The ASCO Post
 - **Accompanying Editorial:** Mishkin et al. Drivers of Clinical Trial Participation – Demographics, Disparities, and Eligibility Criteria. *JAMA Oncol*. January 10, 2019. doi:10.1001/jamaoncol.2018.5949
 - **Audio Interview:** Interview with Joseph M. Unger, PhD, and Dawn Hershman, MD, authors of Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. *JAMA Oncol*, January 10, 2019. Online at: <https://edhub.ama-assn.org/jn-learning/audio-player/17138083>
109. Ramsey SD, **Unger JM**, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices. *JAMA Oncol*. 2019 Apr 1;5(4):497-505. [original article]
110. Cathcart-Rake EJ, Zemla T, Jatoi A, Weaver KE, Neuman H, Kazak AE, Carlos R, Gansauer L, **Unger JM**, Pajewski NM, Kamen C. Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. *Cancer*. 2019 Apr 15;125(8):1313-18. [original article]
111. **Unger JM**, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. *JAMA Network Open*. 2018 Aug 3; 1(4):e181235. [original article]
 - **Media:** UPI.com, US News & World Report, Hutch News, The Medical News, Newswise, MedicalXpress, Doctors Lounge, Physician's Briefing, Drugs.com, Becker's Hospital Review, eCancer, Oregon Public Broadcasting, Medindia, EurekAlert!
 - **Invited Commentary:** McCullough LE, Flowers CR. Identifying and Addressing Disparities in Survival Outcomes for Rural Patients with Cancer. *JAMA Netw Open*. 2018;1(4):e181243. doi:10.1001/jamanetworkopen.2018.1243
 - **Social Media:** Francis Collins, NIH Director; Norman Sharpless, NCI Director
112. Moore HCF, **Unger JM**, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. *J Natl Cancer Inst*. 2019 Feb 1;111(2):210-213. [original article]
 - **Media:** The ASCO Post, Science Daily, Drugs.com, Medical Health News, Physician's Briefing, Medindia, Long Room, ecancer, MedicalXpress, EurekAlert!

113. Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, Hershman DL, **Unger JM**, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Thomas Budd G, Albain KS, Ambrosone CB, McCann SE. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). *Breast Cancer Res.* 2018 Nov 28;20(1):146. [original article]
114. Lipira L, Williams EC, Huh D, Kemp CG, Nevin PE, Greene P, **Unger JM**, Heagerty P, French AL, Cohn SE, Turan JM, Mugavero MJ, Simoni JM, Andrasik MP, Rao D. HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence. *AIDS Behav.* 2019 Aug;23(8):2025-36. [original article]
115. Greenlee H, Lew DL, Hershman DL, Newman VA, Hansen L, Hartman SJ, Korner J, Shi Z, Sardo Molmenti CL, Sayegh A, Fehrenbacher L, Lo S, Klemp J, Rinn K, Robertson JM, **Unger J**, Gralow J, Albain K, Krouse R, Fabian C. Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). *Obesity (Silver Spring).* 2018 Oct;26(10):1539-49. [original article]
116. Shen S, **Unger JM**, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). *Breast Cancer Res Treat.* 2018 Dec;172(3):603-10. [original article]
117. Hershman DL, **Unger JM**, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. *JAMA.* 2018 Jul 10;320(2):167-76. [original article]
 - **Media:** Washington Times, BBC News, HealthDay, Oncology Nurse Advisor, Drugs.com, Physician's Briefing, Medical News Today, MedicalXpress, medwireNews, EurekAlert!
118. **Unger JM**, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL, Iii, Vogelzang NJ, Thompson IM, Jr, Moinpour CM. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). *J Patient Rep Outcomes.* 2018 Jun 13;2:27.
 - **Award:** Second place, the International Society for Quality of Life Research (ISOQOL) Outstanding Article of the Year competition; ISOQOL Annual Meeting, October 23, 2019, San Diego, Ca.
119. **Unger JM**, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. *Cancer Epidemiol.* 2018 Aug;55:117-22. [original article]
120. Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, **Unger JM**, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. *J Clin Oncol.* 2018 Jul 1;36(19):1981-90. [review]
121. †Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, **Unger JM**. Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes

- Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. *J Clin Oncol*. 2018 Sep 10;36(26):2710-17. [original article]
122. **Unger JM**, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM Jr. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst*. 2018 Nov 1;110(11):1208-15. [original article]
 123. **Unger JM**, Vaidya R, Gore JL. Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. *Urol Oncol*. 2019 May;37(5):324-30. [review]
 124. Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, **Unger JM**, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study. *J Natl Cancer Inst*. 2017 Dec 1;109(12). [original article]
 125. Chavez-MacGregor M, **Unger JM**, Moseley A, Ramsey S, Hershman DL. Survival by Hispanic ethnicity among cancer patients participating in SWOG clinical trials. *Cancer*. 2018 April 15;124(8):1760-69. [original article]
 126. Hershman DL, **Unger JM**, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL, Wong SF, Fisch MJ, Henry NL, Albain KS. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). *J Natl Cancer Inst*. 2018 June 1;110(6):669-76. [original article]
 127. † Hershman DL, Till C, Wright JD, Ramsey S, Barlow WE, **Unger JM**. History of Diabetes and Outcome Among Participants 65 or Older in SWOG Clinical Trials. *JCO Clin Cancer Inform*. 2017 Nov;1:1-12. [original article]
 128. Henry NL, **Unger JM**, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade, III, JL. Randomized Multicenter Placebo-Controlled Clinical Trial of Duloxetine versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early Stage Breast Cancer: SWOG S1202. *J Clin Oncol*. 2018 Feb 1;36(4):326-332. [original article]
 129. Lee SM, Hershman DL, Miao J, Zhong X, **Unger J**, Cheung YKK. Estimating Global Treatment Toxicity Burden from Adverse Event Data. *Cancer*. 2018 Feb 15;124(4):858-64. [original article]
 130. Potkul RK, **Unger JM**, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. *NPJ Breast Cancer*. 2016 Aug 10;2:16024. [original article]
 131. Lee SM, Zhang Y, Minasian LM, **Unger JM**, Hershman DL. Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib. *Cancer Invest*. 2017 Aug 9;35(7):484-89. [original article]
 132. **Unger JM**, LeBlanc M, Blanke CD. The effect of positive SWOG treatment trials on population survival. *JAMA Oncol*. 2017 Oct;3(10):1345-51. [original article]
 - **Media:** Reuters, UPI, US News & World Report, MedScape, HealthDay News
 - **Social Media:** NCI Director Dr. Doug Lowy

133. Crew KD, Albain KS, Hershman DL, **Unger JM**, Lo SS. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? *NPJ Breast Cancer*. 2017 May 19;3:20. [review]
134. * Greenlee H, **Unger JM**, LeBlanc M, Ramsey S, Hershman DL. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. *Cancer Epidemiol Biomarkers Prev*. 2017 Jan;26(1):21-29. [original article]
135. † Van Poznak CH, Darke A, Moinpour CM, Bagramian RA, Schubert MM, Gralow JR, Wade JL 3rd, **Unger JM**. Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. *Support Care Cancer*. 2017 Apr;25(4):1191-1199. [original article]
136. †Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, **Unger J**. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. *J Clin Oncol*. 2016 Sep 1;34(25):3014-22. [original article]
137. Moinpour CM, **Unger JM**, Ganz PA, Kornblith AB, Gaynor ER, Bowers MA, Gatti GS, Kaminski MS, Erba HP, Wang T, Yoon J, Press OW, Fisher RI. Seven year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. *J Ca Survivorship*. 2017 Feb;11(1):32-40. [original article]
138. **Unger JM**, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. *Am Soc Clin Oncol Educ Book*. 2016;35:185-98. [original article]
139. **Unger JM**, Till C, Thompson IM, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst*. 2016 Aug 26;108(12). pii: djw168. [original article]
140. **Unger JM**, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. *JAMA Oncol*. 2016 Jul 1;2(7):875-81. [original article]
 - **Accompanying Editorial:** Huntington SF, Gross CP. Negative Studies in Cancer Research: Why the Negativity? *JAMA Oncol*. 2016 Jul 1;2(7):865-6.
141. **Unger JM**, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, Ramsey SD. Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. *Future Oncol*. 2016 May;12(10):1219-31. [original article]
142. Hershman DL, **Unger JM**, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. *JAMA Oncol*. 2016 Apr;2(4):453-61. [original article]
143. Zhong X, Lim EA, Hershman DL, Moinpour CM, **Unger J**, Lee SM. Identifying severe adverse event clusters using the National Cancer Institute's Common Terminology Criteria for Adverse Events. *J Oncol Pract*. 2016 Mar;12(3):e270-e280, 245-6. [original article]

144. **Unger JM**, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. *JAMA Oncol*. 2016 Jan 1;2(1):137-9. [research letter]
 - **Media:** Washington Post, Reuters, UPI, Fox News, Yahoo! News, Business Insider, Biospace, Philly.com, Becker's Hospital Review, Physician's Briefing, Medcity News, Statesman, Tech Times, Pacific Standard, Doctor's Lounge, MedicalXpress, EurekAlert!
 - Included in ASCO's *Clinical Cancer Advances 2017* [J Clin Oncol, 2017 Apr 20;35(12):1341-67]:
145. Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, **Unger JM**, Lew DL, Hansen LH, Meyskens FL, Wade JL, Hershman DL. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. *J Acupunct Meridian Stud*. 2015 Jun;8(3):152-8. [original article]
146. Hershman DL, **Unger JM**, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade III JL, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo-Controlled Trial of Omega-3-Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. *J Clin Oncol*. 2015 Jun 10;33(17):1910-7. [original article]
147. Moore HCF, **Unger JM**, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for Ovarian Protection during Breast Cancer Adjuvant Chemotherapy. *N Engl J Med*. 2015 Mar 5;372(10):923-32. [original article]
 - **Media:** CBS This Morning, Today Show (NBC), ASCO Post, Medscape, Chicago Sun-Times, Cancer Therapy Advisor, MedPage Today
 - Included in ASCO's *Clinical Cancer Advances 2015* [J Clin Oncol, 2015 Mar 1;33(7):786-809]
148. Persky DO, Miller TP, **Unger JM**, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high risk limited stage aggressive B-cell lymphoma: SWOG S0313. *Blood*. 2015 Jan 8;125(2):236-41. [original article]
149. **Unger JM**, Hershman DL, Martin D, Etzioni R, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. *J Natl Cancer Inst*. 2014 Dec 24;107(2):dju412. [original article]
150. Carson WE, **Unger JM**, Sosman JA, Flaherty LE, Tuthill R, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A, Sondak VK. Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-negative Melanoma: Long-Term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival. *Cancer Immunol Res*. 2014 Oct;2(10):981-7. [original article]
151. Friedberg JW, **Unger JM**, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. *Br J Haematol*. 2014 Aug;166(3):382-9. [original article]
152. **Unger JM**, Barlow WE, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. *J Natl Cancer Inst*. 2014 Mar 1;106(3):dju002. [original article]
153. Stiff PJ, **Unger JM**, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as

- consolidation for aggressive Non-Hodgkin's lymphoma. *N Engl J Med*. 2013 Oct 31;369(18):1681-90. [original article]
- **Media:** The ASCO Post, Medical News Today, Health24, Drugs.com, The Medical News, MedicalXpress, MedPage Today, Newswise, EurekAlert!
154. * Press OW, **Unger JM**, Rimsza LM, Friedberg JW, Leblanc ML, Czuczman MS, Kaminski M, Brazier RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher R. A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma based on a Phase III Trial of CHOP-Rituximab vs CHOP + 131Iodine-Tositumomab. *Clin Cancer Res*. 2013 Dec 1;19(23):6624-32. [original article]
 155. Hershman DL, **Unger JM**, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J Clin Oncol*. 2013 Jul 10;31(20):2627-33. [original article]
 156. Bernstein SH, Epner E, **Unger JM**, LeBlanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma; SWOG 0213. *Ann Oncol*. 2013 Jun;24(6):1587-93. [original article]
 157. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, **Unger JM**, Thomas Budd G, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). *Breast Cancer Res Treat*. 2013 Feb;137(3):903-13. [original article]
 158. **Unger JM**, Hershman D, Albain KS, Moinpour CM, Petersen J, Burg K, Crowley JJ. Patient Income Level and Cancer Clinical Trial Participation. *J Clin Oncol*. 2013 Feb 10;31(5):536-42. [original article]
 - **Media:** Reuters, Forbes, Healio, Pacific Standard, MedPage Today
 159. Press OW, **Unger JM**, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Brazier RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A Phase III
 160. Randomized Intergroup Trial of CHOP Chemotherapy Plus Rituximab Compared to CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma (SWOG S0016). *J Clin Oncol*. 2013 Jan 20;31(3):314-20. [original article]
 161. Deverka PA, Lavalley DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, BW Ruffner, Watkins J, Veenstra DL, Baker LH, **Unger JM**, Ramsey SD. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. *J Comp Eff Res*. 2012 July;1(4):359-70. [original article]
 162. Mahadevan D, **Unger JM**, Spier CM, Persky DO, Young F, Leblanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. *Cancer*. 2013 Jan 15;119(2):371-9. [original article]
 163. Stopeck AT, **Unger JM**, Rimsza LM, Leblanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly

- diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. *Blood*. 2012 Aug 9;120(6):1210-7. [original article]
164. Javid SH, **Unger JM**, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara, Jr., PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment to breast cancer clinical trials (SWOG S0316). *Oncologist*. 2012;17(9):1180-90. [original article]
 165. Rimsza LM, **Unger JM**, Tome ME, Leblanc ML. A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma. *PLoS One*. 2011;6(8):e22267. [original article]
 166. Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, **Unger JM**, Flaherty LE, Sondak VK. A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430. *Cancer*. 2011 Oct 15;117(20):4740-6. [original article]
 167. † Hershman DL, **Unger JM**. ‘Minority report’: how best to analyze clinical trial data to address disparities. *Breast Cancer Res Treat*. 2009 December;118(3):519-21. [invited commentary]
 168. Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, **Unger JM**, Brooks TA, Persky DO, Wilkinson ST, Grogan TM, Rimsza LM. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. *Haematologica*. 2010 Apr;95(4):597-603. [original article]
 169. Albain KS, **Unger JM**, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. *J Natl Cancer Inst*. 2009 Jul 15;101(14):984-92. [original article]
 - Included in ASCO’s *Clinical Cancer Advances 2010* [J Clin Oncol, 2010 Dec 20;28(36):5327-47]
 170. Stopeck AT, **Unger JM**, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group study S0108. *Leuk Lymphoma*. 2009 May;50(5):728-35. [original article]
 171. Hershman DL, **Unger JM**, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients:
 172. Retrospective analysis of Southwest Oncology Group Studies S8814/S8897. *J Clin Oncol*. 2009 May 1;27(13):2157-62. [original article]
 - Included in ASCO’s *Clinical Cancer Advances 2009* [J Clin Oncol, 2009 Dec 10;27(35):6052-69]
 173. Bernstein SH, **Unger JM**, Leblanc M, Friedberg J, Miller TIP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG-8516 – the Southwest Oncology Group. *J Clin Oncol*. 2009 Jan 1;27(1):114-119. [original article]
 174. Rimsza LM, Leblanc ML, **Unger JM**, Miller TP, Grogan TM, DO Persky, Martel RR, Sabalos CM, Seligmann B, Brazier RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. *Blood*. 2008 Oct 15;112(8):3425-33. [original article]

175. Persky DO, **Unger JM**, Spier CM, Stea B, Leblanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. *J Clin Oncol*. 2008 May 10;26(14):2258-63. [original article]
176. Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, **Unger JM**, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin's lymphoma: results of a phase III randomized trial by the Southwest Oncology Group (SWOG 9438). *Blood*. 2008 Apr 15;111(8):4048-54. [original article]
177. Ganz PA, Hussey MA, Moinpour CM, **Unger JM**, Hutchins LF, Dakhil SR, Guguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. *J Clin Oncol*. 2008 Mar 10;26(8):1223-30. [original article]
178. Moinpour CM, Hayden KA, **Unger JM**, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology Group. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol*. 2008 Jan 1;26(1):112-20. [original article]
179. Roberts RA, Sabalos CM, Leblanc ML, Martel RR, Frutiger YM, **Unger JM**, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. *Lab Invest*. 2007 Oct;87(10):979-97. [original article]
180. Gotay CC, Moinpour CM, **Unger JM**, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil S, Gross HM, Lippman S, Albain KS. Impact of a peer-delivered Telephone Intervention for women experiencing a breast cancer recurrence. *J Clin Oncol*. 2007 May 20;25(15):2093-9. [original article]
181. Press OW, **Unger JM**, LeBlanc M, Maloney DG, Miller T, Brazier R, Fisher RF. Five year follow-up of a phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I 131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group Protocol S9911. *J Clin Oncol*. 2006 Sep 1;24(25):4143-9. [original article]
182. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, **Unger JM**, Leblanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC, Weisenburger DD, Greiner T, Brazier RM, Miller TP. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood*. 2006 Feb 1;107(3):1101-7. [original article]
183. **Unger JM**, Coltman CA Jr, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. *J Clin Oncol*. 2006 Jan 1;24(1):141-4. [original article]
184. Fisher RI, Leblanc M, Press OW, Maloney DG, **Unger JM**, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. *J Clin Oncol*. 2005 Nov 20;23(33):8447-52. [original article]

185. **Unger JM**, Thompson IM, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. *Cancer*. 2005 Apr 1;103(7):1375-80. [original article]
186. **Unger JM**, LeBlanc M, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. *Urol Oncol*. 2004 Jul-Aug;22(4):362-8. [original article]
187. Rimsza LM, Roberts RA, Miller TP, **Unger JM**, LeBlanc M, Brazier RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood*. 2004 Jun 1;103(11):4251-8. [original article]
188. **Unger JM**, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA 3rd, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA Jr. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial Lecture. *J Clin Oncol*. 2003 Dec 1;21(23 Suppl):246s-252s. [original article]
189. Press PW, **Unger JM**, Brazier RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911. *Blood*. 2003 Sep 1;102(5):1606-12. [original article]
190. Stiff PJ, **Unger JM**, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI; Southwest Oncology Group. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. *Biol Blood Marrow Transplant*. 2003 Aug;9(8):529-39. [original article]
191. Tuthill RJ, **Unger JM**, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. *Amer J Clin Pathol*. 2002 Oct;118(4):504-11. [original article]
192. Whitehead RP, **Unger JM**, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy – a Southwest Oncology Group study. *Invest New Drugs*. 2002 Feb;20(1):105-11. [original article]
193. Sosman JA, **Unger JM**, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA Class I antigen expression on outcome. *J Clin Oncol*. 2002 Apr 15;20(8):2067-75. [original article]
194. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, **Unger JM**, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JB, Noyes RD, Flaherty LE. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: . overall results of a randomized trial of the Southwest Oncology Group. *J Clin Oncol*. 2002 Apr 15;20(8):2058-66. [original article]

195. Press PW, LeBlanc M, Richter AS, Grogan TM, **Unger JM**, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. *J Clin Oncol*. 2001 Nov 15;19(22):4238-44. [original article]
196. Brazier RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, **Unger J**, Miller TP, Tubbs R, Leith C, Fisher RI, Grogan TM. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic and clinical features. *Blood*. 2001 Jun 15;97(12):3713-20. [original article]
197. Whitehead RP, **Unger JM**, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Evaluation of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy; a Southwest Oncology Group study. *Invest New Drugs*. 2001;19(3):239-43. [original article]
198. **Unger JM**, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. *Cancer*. 2001 Mar 15;91(6): 1148-55. [original article]
199. Gaynor ER, **Unger JM**, Miller TP, Grogan TM, White LA Jr, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. *J Clin Oncol*. 2001 Feb 1;19(3):750-5. [original article]
200. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, **Unger JM**, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. *J Clin Oncol*. 2000 May; 18(10): 2010-16. [original article]
201. Hutchins LF, **Unger JM**, Crowley JJ, Coltman CA Jr, Albain KA. Underrepresentation of patients 65 years of age or older in cancer-treatment trials." *N Engl J Med*. 1999 Dec 30;341(27):2061-7. [original article]
202. Margolin K, Liu PY, **Unger JM**, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, Sondak VK. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. *J Cancer Res Clin Oncol*. 1999;125(5):292-96. [original article]
203. **Unger JM**, van Belle G, Heyman A. Cross-sectional versus longitudinal estimates of cognitive change in nondemented older people: a CERAD study. Consortium to Establish a Registry for Alzheimer's Disease. *J Am Geriatr Soc*. 1999 May;47(5):559-63. [original article]
204. Flaherty LE, **Unger JM**, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. *Am J Clin Oncol*. 1998 Dec;21(6):568-72. [original article]
205. Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW 3rd, Fletcher WS, Weiss GR, **Unger JM**, Sondak VK. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. *J Clin Oncol*. 1998 Feb;16(2): 664-9. [original article]

206. Whitehead RP, **Unger JM**, Goodwin JW, Walker MJ, Thompson JA, Flaherty LE, Sondak VK. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study.” *J Immunother*. 1998 Nov;21(6):440-6. [original article]
207. Flaherty LE, Liu PY, **Unger J**, Sondak V. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. *Am J Clin Oncol*. 1997 Dec;20(6):600-4. [original article]

B. Book Chapters

- 1) **Unger JM**. Barriers and Disparities in Access to Cancer Clinical Trials – Causes and Implications. In: Handbook of Statistics. In press.
- 2) **Unger JM**, Vaidya R. Principles of Design and Analysis for Patient-Reported Outcomes. In: Handbook of Statistics. In press.
- 3) **Unger JM**, Hutchins LF, Albain KS. Comprehensive Geriatric Oncology. 2nd ed. London and New York: Taylor & Francis; 2004. Chapter 22, Under-representation of elderly patients in cancer clinical trials: Causes and remedial strategies.
- 4) **Unger JM**, Green S, Albain KS. Breast Cancer in Women of African Descent. The Netherlands: Springer; 2006. Chapter 11, Outcome of African American women with breast cancer in cooperative group clinical trials.

C. Other Publications (correspondence, replies)

- 1) † Fleury ME, **Unger JM**. Patient Willingness to Enroll in Cancer Clinical Trials When Sites Return to Prepandemic Status - Reply. *JAMA Onc*. 2021 Apr 1. Online ahead of print [comment & response]
- 2) Hershman DL, **Unger JM**, Crew K. Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients. *JAMA*. 2018 Dec 4;320(21):2270-71 [comment & response]
- 3) † Hershman DL, **Unger JM**. Reply to T.P. Houston et al. *J Clin Oncol*. 2018 Sep 20;36(27):2810-11 [correspondence]
- 4) **Unger JM**, Barlow WE, Hershman DL. Measuring the real clinical impact of randomized clinical trials in oncology – Reply: Beyond citation counts. *JAMA Oncol*. 2016 Nov 1;2(11):1511 [comment & response]
- 5) Lambertini M, Falcone T, **Unger JM**, Phillips KA, Del Mastro L, Moore HC. Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. *J Clin Oncol*. 2017 Mar;35(7):804-5. [correspondence]
- 6) † Hershman DL, **Unger JM**. Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer-Reply. *JAMA Oncol*. 2016 May 1;2(5):686-7 [comment & response]

- 7) † Hershman DL, **Unger JM**. Reply to L. Gianni et al re: Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Else Thank a Placebo Effect. *J Clin Oncol*. 2015 Dec 20;33(36):4312 [correspondence]
- 8) Moore HC, **Unger JM**, Albain KS. Ovarian protection during adjuvant chemotherapy. *N Engl J Med*. 2015 Jun 4;372(23):2269-70 [correspondence]
- 9) Stiff PJ, **Unger JM**, Fisher RI. The role of myeloablation for lymphoma. *N Engl J Med*. 2014 Feb 6;370(6):575-6 [correspondence]

D. Under Revision

- 1) Cheng G, Chen YC, **Unger JM**, Till C, Zhao YQ. Long-term effect estimation with data linkage. Under revision at *J Am Stat Assoc*.

E. Manuscripts Submitted

- 1) He Y, Xiao H, Dai X, Liu F, **Unger JM**, Liu Z. Healthcare Utilization in the Departments of Obstetrics and Gynecology at the 2-Year Anniversary of the COVID-19 Pandemic: Time Series Analyses in China. Submitted to *BMC Public Health*.
- 2) † Xiao H, Unger JM. Excess All-Cause Mortality in Mainland China after Ending the Zero-COVID Policy: A Systematic Review and Meta-Analysis of COVID-19 Related Mortality. Submitted to *Annals of Internal Medicine*.
- 3) **Unger JM**, Szarama K. Cancer Clinical Trial Participation in Socioeconomically Vulnerable Patients; A Risk Model to Aid in Targeted Interventions. Submitted to *Contemporary Clinical Trials*.
- 4) † Hershman DL, Till C, LeBlanc M, Ramsey S, **Unger JM**. Development and Validation of a Risk Prediction Model for Acute Care Use Among Older Patients with Advanced Cancer on Clinical Trials. Submitted to *JAMA Oncology*.
- 5) † Gupta A, Till C, Vaidya R, Hershman DL, **Unger JM**. Health Care Contact Days in Older Adults Enrolled in SWOG Cancer Clinical Trials. Submitted to *JAMA Oncology*.

8. PATENTS AND OTHER INTELLECTUAL PROPERTY

LM Rimsza, ML LeBlanc, **JM Unger**. Diffuse Large B-Cell Lymphoma Markers and Uses Therefore: EP Patent 2,297,349, 2011; US Patent App. 12/996,112; WO Patent 2,009,149,297

9. FUNDING HISTORY

A. Current

2019 – 2023 Sponsor: The Hope Foundation for Cancer Research (Unger)
 NCE Title: SWOG SDMC Translational/Complex Data Analysis
 Total Costs: \$1,400,000
 Role: PI

2019 – 2025 Sponsor: NCI 1UG1CA189974-06 (Blanke)
 Title: Statistical Center for SWOG NCORP – Cancer Care Delivery Research (CCDR) Program
 Total Costs: \$4,594,549
 Role: Consortium PI

- 2019 – 2025 Sponsor: NCI 1UG1CA189974-06 (Blanke)
Title: Statistical Center for SWOG NCORP – Clinical Trials Program (CTP)
Total Costs: \$14,500,828
Role: Co-Investigator
- 2019 – 2025 Sponsor: U10 CA180819 (LeBlanc)
Title: SWOG Statistics and Data Management Center (SDMC)
Total Costs: \$48,135,258
Role: Co-Investigator
- 2019 – 2027 Sponsor: SWOG-CTP (Tangen)
Title: S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer Total Costs: \$2,000,994
Role: Co-Investigator
- 2020 – 2025 Sponsor: National Institutes of Health (Shankaran)
Title: Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention
Total Costs: \$825,000
Role: Co-Investigator
- 2020 – 2027 Sponsor: SWOG-CTP (Unger)
Title: S1925: Randomized Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study
Total Costs: \$407,479
Role: PI
- 2021–2026 Sponsor: NIH/ Regents of the University of Michigan (Henry)
Title: Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast Cancer
Total Costs: \$110,005
Role: Consortium PI
- 2022 – 2024 Sponsor: The Hope Foundation for Cancer Research (Unger)
Title: Socioeconomic Disparities in Patient-Reported Outcomes Among Cancer Clinical Trial Participants
Total Costs: \$62,425
Role: PI
- 2023-2025 Sponsor: Andy Hill Cancer Research Endowment (CARE) FY23-IDCT-04 (Unger)
Title: Optimizing clinical trials access to ensure inclusion and diversity
Total Costs: \$999,559
Role: PI
- 2023-2027 Sponsor: NIH CA277043-01 (Hertz)
Title: Development of an Integrated Risk Prediction Model of TIPN
Total Costs: \$294,060 subaward funds
Role: Co-Investigator
- 2023-2030 Sponsor: SWOG-CTP S2209 (Unger)
Title: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront three-drug induction regimens followed by double- or single-agent maintenance

Total Costs: \$144,148

Role: PI

- 2023-2030 Sponsor: SWOG-CTP S2213 (Unger)
 Title: A Phase II, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
 Total Costs: \$312,352.50
 Role: PI
- 2024-2028 Sponsor: NIH CA274541 (Ramsey)
 Title: Disparities in Financial and Clinical Outcomes among Commercially Insured Cancer Patients following the Affordable Care Act
 Total Costs: \$1,610,400
 Role: Co-Investigator
- 2024-2029 Sponsor: NIH CA293394 (Veenstra, Hawley)
 Title: A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance
 Total Costs: \$473,063.00 subaward funds
 Role: Consortium PI

B. Pending

- 2024 – 2025 Sponsor: NIH 1R37CA218118-01A1 (Hamilton-Reeves)
 Title: Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes- MERIT extension
 Total Costs: 66,653.00
 Total Costs Awarded to Date 32,835.00
 Role: Consortium PI
- 2024 - 2029 Sponsor: NIH CA279010-01A1 (Brenner, Shah (MPI))
 Title: Expanding access to colorectal cancer screening through community pharmacies: The PharmFIT study
 Total Costs: \$1,582,398
 Role: Co-Investigator

C. Past

- 2009 – 2015 Sponsor: NCI SWOG Support Grant (HOPE Foundation) (Baker)
 Title: Organizational infrastructure support to link the SWOG database to Medicare claims
 Role: Consortium PI
- 2011 Sponsor: Susan G. Komen for the Cure®, 2011 Conquer Cancer Foundation of ASCO Improving Cancer Care Grant (ICCG) (Hershman)
 Title: Text messaging to reduce early discontinuation of adjuvant hormonal therapy in breast cancer: randomized trial
 Role: Co-Investigator
- 2011 Sponsor: Susan G. Komen for the Cure®, 2011 Conquer Cancer Foundation of ASCO Improving Cancer Care Grant (ICCG) (Hershman)
 Title: Text messaging to reduce early discontinuation of adjuvant

hormonal therapy in breast cancer: randomized trial
Role: Co-Investigator

- 2013 – 2017 Sponsor: NCI R01 CA166084-01 (Hershman)
Title: Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors
Role: Co-Investigator
- 2014 – 2016 Sponsor: Colman Fellowship Award (HOPE Foundation) (Unger)
Title: The generalizability of clinical trial treatment effects
Role: PI
- 2016 – 2019 Sponsor: HOPE Foundation (Unger)
Title: SWOG NCORP Pilot Grants Program
Role: PI
- 2016 – 2019 Sponsor: PG007377-01 Susan G. Komen Foundation (Hershman)
Title: Comorbidity, Toxicity and Breast Cancer Survival Among Women On and Off Clinical Trials
Role: Consortium PI
- 2019 – 2020 Sponsor: The Albertsons Companies Foundation/Safeway (Jones)
Title: Pilot of Precision Patient-Reported Outcomes for Clinical Trials and Clinical Care
Role: Co-Investigator
- 2020 Sponsor: University of Washington
Title: Teaching contract for HSERV 524 Advanced Health Services Research Methods II: Hierarchical and Incomplete Data
Role: Instructor
- 2020 – 2023 Sponsor: American Cancer Society (Unger)
Title: Insurance Disparities in Cancer Clinical Trials and the Affordable Care Act
Role: PI

10. PUBLIC HEALTH PRACTICE ACTIVITIES

N/A

11. CONFERENCES AND SYMPOSIUMS

A. PRESENTATIONS, NATIONAL AND INTERNATIONAL

1. **“Patient enrollment to industry- versus NIH-sponsored cancer clinical trials”**
Oral Session, 2024 ASCO Quality Care Symposium (September 27, 2024; San Francisco, CA)
2. **“Patient-Reported Fatigue and Risk of Treatment-Related Adverse Events”**
Invited Speaker, Best of SWOG at ASCO (June 26, 2024; virtual)
3. **“Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and NCI Studies”**
Invited Speaker, DIA Annual Meeting (June 18, 2024; San Diego, CA)

4. **“Patient-Reported Fatigue and Risk of Treatment-Related Adverse Events in Patients Receiving Systemic Therapy in Cancer Clinical Trials”**
Oral Session, 2024 ASCO Annual Meeting (June 3, 2024; Chicago, IL)
5. **“The Problem of URM Representation in Cancer Clinical Trials”**
Invited Speaker, The 6th Stat4Onc Annual Symposium (May 12, 2023; Portland, OR; virtual)
6. **“Barriers to Clinical Trial Participation: How to Ensure Diverse Populations in Clinical Research”**
Invited Speaker, Moffit Cancer Center, Grand Rounds (October 26, 2023, Tampa Bay, FL)
7. **“Long-term complications of prostate cancer”**
Invited Speaker, Festshrift for Dr. Ian Thompson (October 20, 2023, San Antonio, TX)
8. **“The ACA Medicaid Expansion and Enrollment of Patients with Medicaid Insurance to Cancer Clinical Trials”**
Invited Speaker, NCI Community Oncology Research Program Workshop, SWOG Cancer Research Network Group Meeting (October 10, 2023, Chicago, IL)
9. **“Sex differences in severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in Cancer clinical trials: An evidentiary perspective.”**
Invited Speaker, Major Symposium, AACR Annual Meeting (April 18, 2023, Orlando, FL)
10. **“Ensuring Diverse Population in Clinical Trial Research”**
Invited Speaker, Foundation CEOs meeting (April 6, 2023; virtual)
11. **“Increasing Older Adult Accrual to NCI Cancer Clinical Trials: An Evidentiary, Design and Statistical Perspective”**
Invited Speaker, NCI’s Cancer, Aging, and Comorbidities Webinar Series (February 1, 2023; virtual)
12. **“Population, Clinical, and Scientific Impact of National Cancer Institute’s National Clinical Trials Network Treatment Studies”**
Invited Speaker, Best of SWOG at ASCO 2022 (February 1, 2023; virtual)
13. **“When to Adjust for Multiplicity: Secondary Aims”**
Invited Speaker, NCI’s Community Oncology Research Base, Statistical Leads Meeting (November 29, 2022; virtual)
14. **“Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Clinical Trials”**
Invited Speaker, Friends of Cancer Research Annual Meeting (November 17, 2022, Washington, DC)
15. **“Socioeconomic Deprivation and Cancer Outcomes”**
Invited Speaker, SWOG Latin America Initiative Conference (November 10, 2022; Montevideo, Uruguay; virtual)
16. **“Patient Reported Outcomes (PROs): Principles of Study Design and Analysis”**
Invited Speaker, SWOG Latin America Initiative Conference (November 10, 2022; Montevideo, Uruguay; virtual)
17. **“When to Adjust for Multiplicity”**
Invited Panelist, National Cancer Institute, Statistical Adjustment for Multiplicity Workshop (October 26-27, 2022; virtual)
18. **“Use of Patient-Reported Outcomes in SWOG Trials: Past, Present, and Future”**

Invited Speaker, SWOG NCORP Workshop (October 19, 2022, Chicago, IL)

19. **“Adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose interferon or ipilimumab in patients with resected melanoma; SWOG S1404, a randomized clinical trial”**
Invited Speaker, National Cancer Institute, 2022 NCORP Annual Meeting (August 25, 2022; Bethesda, MD – virtual)
20. **“Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.”**
Oral Abstract Session, Care Delivery and Regulatory Policy, ASCO Annual Meeting (June 6, 2022; Chicago, IL)
21. **“The Medicaid expansion of the Affordable Care Act and participation of patients with Medicaid in cancer clinical trials”**
Oral Abstract Session, Health Services Research and Quality Improvement, ASCO Annual Meeting (June 4, 2022; Chicago, IL)
22. **“Clinical Trials and Disparities in cancer care”**
Invited Keynote Speaker, Binaytara Foundation, 2022 Summit on Cancer Health Disparities (May 1, 2022; Seattle, WA)
23. **“Leveraging Linked Clinical Trial Data to Examine the Scientific, Clinical, and Population Impact of NCI-Sponsored Cancer Clinical Trials”**
Invited Speaker, Department of Health Services Research Seminar (February 3, 2022; virtual)
24. **“Ensuring Diverse Populations in Clinical Research”**
Invited Speaker, Latin American Symposium, SWOG Group Meeting (April 7, 2022, Seattle, WA)
25. **“Overcoming Barriers to Clinical Trial Recruitment”**
Panelist, NCCN Academy for Excellence & Leadership in Oncology (April 13, 2022; virtual)
26. **“Barriers and Disparities to Participation in Cancer Clinical Trials: Framework and Evidence”**
Invited Speaker, Stat4Onc Annual Symposium (May 6, 2022; virtual)
27. **“Geographic Distribution and Clinical Outcomes for Rural versus Urban Cancer Patients Treated in Clinical Trials”**
Invited Speaker, Heartland Cancer Research NCORP Annual Meeting (April 30, 2022; virtual)
28. **“Barriers and Disparities in Clinical Trial Participation: Framework, Evidence, and Steps Forward”**
Invited Speaker, The University of Kansas Center Research Week (November 19, 2021; virtual)
29. **“Cancer Disparities in Clinical Trials: Access and Outcomes”**
Invited Speaker, Cancer Intervention and Surveillance Modeling Network (CISNET) 2021 Annual Meeting (November 18, 2021; virtual)
30. **“The Impact of the COVID-19 Pandemic on Cancer Clinical Trial Participation and New Study Activations”**
Invited Speaker, NCORP Workshop, SWOG Semiannual Meeting (October 12, 2021; virtual)
31. **“Nationally Representative Estimates of the Participation of Cancer Patients in Clinical Research Studies According to the Commission on Cancer”**
Oral Presentation, ASCO Quality Care Symposium; Boston, MA (September 24, 2021; virtual)
32. **“Population, Clinical, and Scientific Impact of National Cancer Institute-Sponsored Clinical Trial Network Treatment Studies”**
Proffered Paper, European Society for Medical Oncology (ESMO) Congress 2021; Paris, France (September 20, 2021; virtual)
33. **“Health-Related Quality of Life Correlative Studies in SWOG: Results, Impact, and Lessons Learned”**

- Invited Speaker, National Cancer Institute Community Oncology Research Program Annual Meeting; Bethesda, MD (August 27, 2021; virtual)
34. **“Medicaid Patients in NCI Sponsored Network Group Clinical Trials and the Clinical Treatment Act”**
Invited Speaker, National Cancer Institute Community Oncology Research Program Annual Meeting; Bethesda, MD (August 26, 2021; virtual)
35. **“Beyond the Numbers - Accruing Patients to Clinical Trials in the Rural Sector”**
Invited Keynote Speaker, Masonic Cancer Alliance Annual Meeting, The University of Kansas Cancer Center; Kansas City, MO (June 25, 2021; virtual)
36. **“Access and Outcomes for Minority/Underserved Populations in NCI-Sponsored Network Group Cancer Clinical Trials”**
Invited Speaker, SWOG-NCORP Symposium to Address Disparities in Clinical Trials Accrual (May 21, 2021; virtual)
37. **“Patient Reported Outcomes in Cancer Clinical Trials: Key Design and Analysis Principles”**
Invited Lecturer, Clinical Trials Training Course of SWOG’s Latin America Initiative; Mexico City, Mexico (April 29, 2021; virtual)
38. **“Stratified and Embedded Cohort Designs to Improve Assessment of Older Patients in Clinical Trials”**
Invited Speaker, NCI and Cancer Moonshot symposium, “Engaging Older Adults in the NCI Clinical Trials Network: Challenges and Opportunities” (April 26, 2021; virtual)
39. **“Patient enrollment to cancer clinical trials: Much greater than it seems (when patients are asked)”**
Invited Speaker, Best of SWOG at ASCO, 2020 (January 27, 2021; virtual)
40. **“Statistical Issues in Cancer Control Research”**
Invited Speaker, Conference on Clinical Research as a Tool for Addressing Cancer Burden in the Latin American Population; Santiago, Chile (November 12, 2020; virtual)
41. **“A Novel Data Linkage to Examine the Long-Term Adverse Consequences of Cancer Treatment: The SWOG-Medicare Database”**
Invited Speaker, National Cancer Policy Forum Virtual Workshop In Collaboration with the Forum on Aging, Disability, and Independence: Addressing the Adverse Consequences of Cancer Treatment: A Workshop; Bethesda, MD (November 10, 2020; virtual)
42. **“Geographic Distribution and Clinical Outcomes for Rural versus Urban Cancer Patients Treated in Clinical Trials”**
Invited Speaker, Community Cancer Education Program, OHSU Knight Cancer Network, Cancer clinical Trials: The Role of Primary Care Providers in a Rural Setting; Coos Bay, OR (October 16, 2020; virtual)
43. **“‘When offered to participate’: A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials”**
Oral Session, ASCO Quality Care Symposium (October 10, 2020; virtual)
44. **“The Scientific, Clinical, and Population Impact of SWOG Cancer Research Network Clinical Trials”**
Invited Speaker, Oishi Symposium, SWOG Annual Meeting (September 24, 2020; virtual)
45. **“Demographic and Socioeconomic Representativeness of NCI-Sponsored Cancer Clinical Trials”**
Invited Speaker, NCI Community Oncology Research Program Workshop, SWOG Annual Meeting (September 23, 2020; virtual)
46. **“Insurance Disparities in Cancer Clinical Trials”**
Invited Speaker, CEO’s Against Cancer (September 22, 2020; virtual)
47. **“Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute”**

Invited Speaker, NAVIGATE, the NCI and VA Interagency Group to Accelerate Enrollment to Clinical Trials (August 20, 2020; virtual)

48. **“Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute”**
Poster, American Association for Cancer Research Annual Meeting (June 22-24, 2020; virtual)
49. **“Approaches to Utilize Real-world Data to Understand Outcomes with Specific Therapies in Racial and Ethnic Minorities”**
Session Chair, FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials; Bethesda, MD (February 13, 2020)
50. **“Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies with Guideline Care and New Drug Indications”**
Invited Speaker, NCI Patient Advocate Steering Committee (November 18, 2019; virtual)
51. **“Access to Care Through Clinical Trials: Structural Barriers, The Role of Socioeconomic Status, and Models for Patient Financial Support”**
52. Invited Keynote Speaker, National Coalition for Cancer Survivorship, Cancer Policy Roundtable, Washington, DC (November 14, 2019)
53. **“Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials”**
54. Poster, ASCO Quality Care Symposium; San Diego, CA (September 6, 2019)
55. **“Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions”**
56. Oral Plenary Session, ASCO Quality Care Symposium; San Diego, CA (September 6, 2019)
57. **“Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy, and Targeted Agent Cancer Clinical Trials”**
58. Poster, American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL (June 3, 2019)
59. **“The Impact of NCI-Sponsored Network Group Clinical Trials on Guideline Care and New Drug Indications”**
60. Poster, American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL (June 1, 2019)
61. **“Structural, Clinical, and Physician/Patient Barriers to Clinical Trial Participation”**
62. Invited Speaker, Hutchinson Institute for Cancer Outcomes Research (HICOR) Value in Cancer Care Summit; Seattle, WA (May 13, 2019)
63. **“Long Term Prostate Cancer Risk in the Prostate Cancer Prevention Trial”**
64. Invited Speaker, Clinical Trials and Translational Research Advisory Committee, National Cancer Institute, National Institutes of Health, Bethesda, MD (November 7, 2018)
65. **“The Prevalence of Viral Infection among Newly Diagnosed Cancer Patients: SWOG S1204”**
66. Invited Speaker, SWOG Fall 2018 Group Meeting, Cancer Care Delivery Research Committee; Chicago, IL (October 4, 2018)
67. **“Key Design and Analysis Principles for Quality of Life and Patient-Reported Outcomes in Clinical Trials”**
68. Invited Speaker, SWOG Fall 2018 Group Meeting, Symptom Control and Quality of Life Committee; Chicago, IL (October 4, 2018)
69. **“SWOG’s Patient Reported Outcomes Core”**
70. Invited Speaker, SWOG Fall 2018 Group Meeting, SWOG NCORP Executive Committee; Chicago, IL (October 3, 2018)
71. **“Geographic Distribution and Survival Outcomes for Rural Patients with Cancer Treated in Clinical Trials”**

72. Invited Speaker, SWOG NCORP Research Base Clinical Trials Workshop; Chicago, IL (October 3, 2018)
73. **“What Big Data Can Teach Us about Real-World Immune-Therapeutics Use and Toxicity”**
Invited Speaker, SWOG Immunotherapy Retreat; Salt Lake City, Utah (July 20, 2018; virtual)
74. **“Race Disparities in Participation in Clinical Trials for Myeloma”**
Invited Speaker, FDA Symposium on racial and ethnic representation in clinical trials for myeloma; White Oak Campus, Washington, DC (January 8, 2019)
75. **“Income and Age Disparities in Access to Cancer Clinical Trials: Models, Evidence, and Implications”**
Invited Speaker, 12th Annual Texas Conference on Health Disparities; Dallas, TX (June 9, 2017)
76. **“The Impact of Positive SWOG Treatment Trials on Survival of Patients in the U.S.”**
Poster Discussion, American Society of Clinical Oncology Annual Meeting; Chicago, IL (June 5, 2017)
77. **“The Scientific Impact of Randomized Phase III Prevention Trials”**
Poster, American Society of Clinical Oncology Annual Meeting; Chicago, IL (June 5, 2017)
78. **“Cancer Disparities Research in SWOG”**
Invited Speaker, SWOG NCORP Research Base Clinical Trials Workshop; San Francisco, CA (September 13, 2016)
79. **“The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies”**
Session Chair and Presenter, Education Session on Barriers to Clinical Trials, American Society of Clinical Oncology Annual Meeting; Chicago, IL (June 4, 2016)
80. **“The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials”**
Oral Presentation, Scientific Session, Cancer Care Delivery Research Committee, Southwest Oncology Group Semiannual Meeting; San Francisco, CA (April 29, 2016)
81. **“NCORP vs. NCTN Trials: Why and How They’re Different”**
Invited Speaker, SWOG NCORP Research Base Clinical Trials Training Workshop; San Francisco, CA (October 7, 2015)
82. **“PRO Design for the Master Lung Protocol: Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (“Lung-MAP”)”**
Invited Speaker, NCI Precision Medicine and PROs Workshop; Bethesda, MD (September 28, 2015)
83. **“Models to Identify and Support Clinical Trial Participants”**
Invited Speaker, NIH Seminar on the Enrollment and Retention of Participants in NIH-funded Clinical Trials, NIH, Bethesda, MD (July 25, 2014)
84. **“The Generalizability of Standard Arm Outcomes for Cancer Patients Treated In and Out of Clinical Trials”**
Plenary Presentation, Southwest Oncology Group Semiannual Meeting; San Francisco, CA (May, 2014)
85. **“Enhancing the Conduct of Clinical Trials”**
Invited Discussant, Health Services Oral Session, American Society of Clinical Oncology Annual Meeting; Chicago, IL (June 3, 2013)
86. **“The Diffusion of Docetaxel for Patients Presenting with Metastatic Prostate Cancer”**
Invited Speaker, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting; San Francisco, CA (May 2, 2013)
87. **“The Generalizability of Standard Arm Outcomes for Cancer Patients Treated In and Out of Clinical Trials”**
Invited Speaker, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting; Chicago, IL (October, 2012)
88. **“The Role of Socioeconomic Status in Cancer Clinical Trial Participation”**

Oral Presentation, AcademyHealth Conference; Orlando, FL (June 18, 2012)

89. **“Demographic Variables, Patient Income Level and Cancer Clinical Trial Participation”**
Oral Presentation, American Society of Clinical Oncology (ASCO) Quality Care Symposium; Chicago, IL (June 3, 2012)
90. **“Patient Income Level and Cancer Clinical Trial Participation: Findings from a Survey Study”**
Invited Speaker, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting; San Francisco, CA (April 12, 2012)
91. **“The Cost Effectiveness and Cost Utility of Finasteride for the Prevention of Prostate Cancer”**
Invited Speaker, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting; San Francisco, CA (April, 2011)
92. **“The SWOG Clinical Trials Database For Health Outcomes, Disparities, & Comparative Effectiveness Analyses: Past, Present, and Future”**
Invited Speaker, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting; San Francisco, CA (April 15, 2010)
93. **“Enrollment Patterns in NCI-Sponsored Clinical Trials by Sex, Race/Ethnicity, and Age”**
Poster Discussion, American Society of Clinical Oncology Annual Meeting; New Orleans, LA (June 6, 2004)
94. **“Accrual Patterns of the Southwest Oncology Group by Sex, Race/Ethnicity, and Age: Updated and Expanded Analyses”**
Plenary Session, Southwest Oncology Group Semiannual Meeting; Huntington Beach, CA (May, 2004)
95. **“The Person-Years Saved Model and Other Methodologies for Assessing the Population Impact of Cancer Prevention Strategies”**
Invited Speaker, Consensus Conference, Chemoprevention of Prostate Cancer; Reston, VA (March 5, 2004)
96. **“Survival and Toxicity by Sex in SWOG Clinical Trials”**
Invited Speaker, Committee on Special Populations, Southwest Oncology Group Semiannual Meeting (October 4, 2003)
97. **“Patterns of Overall Survival by Race in Patients Treated in Clinical Trials”**
Poster Discussion, American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL (June 1, 2003)
98. **“African Americans Have Worse Survival in Hormone-Related Cancers”**
Plenary Session, Southwest Oncology Group Semiannual Meeting; San Diego, CA (April 12, 2003)
99. **“Is There a Future for Federally Supported Cancer Clinical Trials?”**
Plenary Session, Southwest Oncology Group Semiannual Meeting; Chicago, IL (October 27, 2001)
100. **“Survival Patterns for Black Patients in Hormone-Related Cancers”**
Invited Speaker, Committee on Women and Special Populations, Southwest Oncology Group Semiannual Meeting; New Orleans, LA (October 13, 2000)
101. **“Southwest Oncology Group Accrual by Sex, Race, and Age, Compared to US Population Rates”**
Poster Discussion, American Society of Clinical Oncology (ASCO) Annual Meeting; Los Angeles, CA (May 18, 1998)
102. **“Enrollment to SWOG Clinical Trials by Demographic Factors Compared to US Population Rates”**
Plenary Session, Southwest Oncology Group Semiannual Meeting; Atlanta, GA (April 26, 1998)

B. PRESENTATIONS, LOCAL

- 1) **“Cancer Outcomes Research Using Clinical Trial Databases: A Framework and Case Studies”**
Invited Speaker, BOC/CEPC Symposium, Fred Hutchinson Cancer Center, Seattle, WA (November 14, 2024)

- 2) **“Barriers to Clinical Trial Participation: How to Ensure Diverse Populations in Clinical Research”**
Invited Speaker, Fred Hutchinson Cancer Center Board of Advisors, Fred Hutchinson Cancer Center, Seattle, WA (October 13, 2023)
- 3) **“Cancer Health Disparities and Cancer Clinical Trials in the COVID Era”**
Invited Speaker, American Cancer Society Health Forum, Fred Hutchinson Cancer Center, Seattle, WA (November 1, 2022)
- 4) **“The COVID-19 Pandemic, Cancer Clinical Trial Participation and New Study Activations”**
Invited Speaker, Public Health Sciences All-Staff Meeting, Seattle, WA (April 14, 2022; hybrid)
- 5) **“Barriers and Disparities to Participation in Cancer Clinical Trials: Framework and Evidence”**
Presentation, Fred Hutch Equity and Inclusion in Clinical Trials Task Force; Fred Hutchinson Cancer Center; Seattle, WA (January 20, 2022; virtual)
- 6) **“The Impact of the COVID-19 Pandemic on Cancer Clinical Trial Participation and New Study Activations”**
Presentation, PHS Faculty Meeting; Fred Hutchinson Cancer Center; Seattle, WA (November 21, 2021; virtual)
- 7) **“The Scientific, Clinical, and Population Impact of NCI-Sponsored National Clinical Trial Network (NCTN) Clinical Trials”**
Invited Speaker, Data of Cancer Research Seminar Series; Fred Hutchinson Cancer Center; Seattle, WA (November 15, 2021; virtual)
- 8) **“Barriers and Disparities to Clinical Trial Participation: A Problem of the System, Not the Patient”**
Invited Speaker, Science for Staff; Fred Hutchinson Cancer Center; Seattle, WA (June 15, 2021; virtual)
- 9) **“Persistent disparity: Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials”**
Invited Speaker, Long-Term Effects and Survivorship Seminar; Fred Hutchinson Cancer Center; Seattle, WA (March 16, 2021; virtual)
- 10) **“‘When offered to participate’: A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials”**
Invited Speaker, Cancer Prevention Faculty Meeting, Fred Hutchinson Cancer Center; Seattle, WA (March 15, 2021)
- 11) **“Context Matters: Examining the Clinical Trial Endeavor as a Research Process”**
Seminar, Public Health Sciences Division, Fred Hutchinson Cancer Center; Seattle, WA (March 4, 2020)
- 12) **“SWOG Clinical Trials and Correlative Studies with Cancer Registry and Medicare Claims Data”**
Seminar, PHS Long Term Effects and Survivorship Affinity Group Seminar Series, Fred Hutchinson Cancer Center; Seattle, WA (March 11, 2019)
- 13) **“The Use of Clinical Trial Databases for Secondary Data Analysis: Strategies, Novel Features, and Linkages”**
Seminar, The Data of Cancer Research Seminar Series, Fred Hutchinson Cancer Center, Seattle (March 18, 2019)
- 14) **“Using Big Data Strategies to Extend the Life of Clinical Trials”**
Seminar, Clinical Trial Affinity Group, Fred Hutchinson Cancer Center; Seattle, WA (September 27, 2018)
- 15) **“The Prevalence of Viral Infection among Newly Diagnosed Cancer Patients: SWOG S1204”**
Invited Speaker, Medical Oncology Sections Meeting, Seattle Cancer Care Alliance; Seattle, WA (September 6, 2018)
- 16) **“CIPN Research in SWOG and the NCI’s CIPN Longitudinal Study Working Group”**
Panel Presenter, PHS Long Term Effects/Survivorship & the Cancer Epidemiology/Prevention Affinity Groups, Fred Hutchinson Cancer Center; Seattle, WA (June 26, 2017)

- 17) **“Recent Positive SWOG Trials in the NCORP Research Base”**
Invited Speaker, Cancer Research and Biostatistics Lunch and Learn Seminar Series; Seattle, WA (March 8, 2017)
- 18) **“The Role of Clinical Trials in Scientific Pursuit”**
Invited Speaker, Mini-TED Talk, Public Health Sciences Faculty Meeting, Fred Hutchinson Cancer Center; Seattle, WA (November 7, 2016)
- 19) **“Using Medicare claims data to identify late effects following treatment on SWOG clinical trials”**
Seminar, Long Term Effects and Survivorship Affinity Group, Fred Hutchinson Cancer Center; Seattle, WA (June 12, 2015)

12. UNIVERSITY SERVICE

Jan-Mar, 2016	Instructor: University of Washington, Department of Health Services Research HSERV 524: Advanced Methods for Health Services Research
Jan-Mar, 2020	Instructor: University of Washington, Department of Health Services Research HSERV 524: Advanced Methods for Health Services Research

13. PROFESSIONALLY-RELATED COMMUNITY SERVICE

2016 – current	University of Washington, Presenter, Fred Hutch Visit Day for new students in the Department of Health Systems and Population Health
2017	Fred Hutchinson Cancer Center, Search Committee Member, Faculty Position in Behavioral Science in the Public Health Sciences Division
2017	Fred Hutchinson Cancer Center, Premier Chef’s Dinner Reviewer
2018	Fred Hutchinson Cancer Center, Bid and Proposal Reviewer
2018 – current	University of Washington, Developing Data-Driven Cancer Researchers Training Grant (T32) mentor
2018 – current	University of Washington, AHRQ National Research Service Award Institutional Research Grant (T32) mentor in the department of Health Systems and Population Health
2021	Fred Hutchinson Cancer Center, Search Committee Member, Faculty Position in Implementation Science in the Public Health Sciences Division
2021	Fred Hutchinson Cancer Center, Search Committee Member, Faculty Position in Health Economics/Health Services Research with the Hutchinson Institute for Cancer Outcomes Research in the Public Health Sciences Division
2021 – current	Fred Hutchinson Cancer Center, Population Sciences Research Group Reviewer
2022 – 2024	Co-Chair, Fred Hutchinson Cancer Center, Task Force on Inclusion and Equity in Research

14. [OTHER PERTINENT INFORMATION AS NEEDED]

A. Television and Radio Interviews

- 1) **KOMO News Live, Seattle.** April 3, 2024.
- 2) **Sirius XM Radio.** The Business of Health Care. “The Role of Clinical Trial Participation in Cancer Research”, September 6, 2018. Available at: <https://shows.pippa.io/wbr-guest/episodes/a-loaiza-bonilla-g-huang-j-unger>

- 3) **BBC Newsday**. Obstacles to clinical trial participation. February 19, 2019. Available at: <https://www.bbc.co.uk/programmes/w172w1g0c6gky9q>. Minute 43:00.

B. Webinars

- 1) Invited Presenter and Panelist, PCORI Metastatic Key Stakeholder Webinar Series, “Access Disparities in Cancer Care and Cancer Research: Survival Outcomes for Rural vs. Urban Cancer Patients Treated in Clinical Trials”. January 16, 2019. Recording available at: <https://www.youtube.com/watch?v=S4PTS4hZWbQ&feature=youtu.be>
- 2) Presenter, Cancer Care Delivery Research Landscape Survey, February 17, 2017. Recording available at: <https://www.youtube.com/watch?v=S4PTS4hZWbQ&feature=youtu.be>

15. TEACHING HISTORY

Jan-Mar, 2016 Instructor: University of Washington, Department of Health Services Research
HSERV 524: Advanced Methods for Health Services Research

Jan-Mar, 2020 Instructor: University of Washington, Department of Health Services Research
HSERV 524: Advanced Methods for Health Services Research

15. ADVISING AND FORMAL MENTORING

A. Students Graduated as Member, Dissertation Committee

2018 Lauren Lipira (PhD, Health Services Research): “Social and behavioral determinants of HIV care and outcomes among a sample of African-American women living with HIV”

2019 Janeth Sanchez (PhD, Health Services Research): “Assessing disparities in colorectal cancer postoperative-related outcomes”

2019 Sarah Hohl (PhD, Health Services Research): “Assessing Behavior Change and Establishing Outcomes to Propose a Conceptual Model of Transdisciplinary Public Health”

2019 Natalia Oster (PhD, Health Services Research): “Improving childhood vaccine coverage: Understanding factors associated with receipt of Hepatitis B and other recommended vaccines.”

B. Postdoctoral Fellows

2017-2019 Van Thi Ha Nghiem, PhD

2020-present Hong Xiao, PhD (promoted to Staff Scientist in 2024)

C. Other Mentoring Roles

2021-present Catherine Troja, MPH, University of Washington, Doctoral Program in Epidemiology (Graduation Student Representative)

2022-present Mariama Bah, University of Washington, Masters Program in Epidemiology (advisor)

2022-present Nicole Caston, MPH, University of Alabama, Doctoral Program in Epidemiology (external advisor)